Nautilus Biotechnology Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
NAUT$2.32-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
Nautilus Biotechnology, Inc.Consolidated Statements of Stockholders’ EquityYears Ended December 31, 2023 and 2022
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · Shares · Amount | ||||||
| Balances at December 31, 2021 | 124,303,083 | $12 | $444,388 | $(184) | $(80,640) | $363,576 |
| Issuance of common stock upon exercise of vested stock options | 463,207 | — | 330 | — | — | 330 |
| Issuance of common stock under employee stock purchase plan | 99,195 | — | 232 | — | — | 232 |
| Stock-based compensation expense | — | — | 10,380 | — | — | 10,380 |
| Other comprehensive loss | — | — | — | (1,670) | — | (1,670) |
| Net loss | — | — | — | — | (57,924) | (57,924) |
| Balances at December 31, 2022 | 124,865,485 | 12 | $455,330 | $(1,854) | $(138,564) | $314,924 |
| Issuance of common stock upon exercise of vested stock options | 70,865 | — | 104 | — | — | 104 |
| Issuance of common stock under employee stock purchase plan | 132,251 | 1 | 263 | — | — | 264 |
| Stock-based compensation expense | — | — | 12,137 | — | — | 12,137 |
| Other comprehensive income | — | — | — | 1,599 | — | 1,599 |
| Net loss | — | — | — | — | (63,675) | (63,675) |
| Balances at December 31, 2023 | 125,068,601 | 13 | $467,834 | $(255) | $(202,239) | $265,353 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.